+50.0%
EXPE vs GSK
+14.9%
+35.1%
-37.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +10.5% | +5.0% | +5.5% | +9.6% |
| 7D | +14.6% | +4.9% | +9.7% | +13.7% |
| 30D | +21.4% | +9.9% | +11.5% | +20.2% |
| 3M | +1.4% | +0.2% | +1.2% | +0.8% |
| 6M | +28.6% | +2.3% | +26.3% | +28.4% |
| YTD | +12.1% | +7.1% | +5.1% | +5.6% |
| 1Y | +50.0% | +13.1% | +36.9% | +41.4% |
| All | +50.0% | +14.9% | +35.1% | +41.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling